InMed Pharmaceuticals Inc expected to post a loss of 34 cents a share - Earnings Preview

InMed Pharmaceuticals

22/09/2021 13:45

* InMed Pharmaceuticals Inc  INM.OQ   INM.O  is expected
to report results on September 24.
​* Refinitiv's mean analyst estimate for InMed Pharmaceuticals
Inc is for a loss of 34 cents per share. 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for InMed
Pharmaceuticals Inc is $11.5​, about 83.3% above​ its last
closing price of $1.92. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.24       -0.24      -0.41     Missed  -70.8
 Dec. 31 2020  -0.24       -0.24      -0.41     Missed  -70.8
                                                        ​
 ​​            ​                                        ​
                                                        ​
 This summary was machine generated September 22 at 12:44 GMT. 
All figures in US dollars unless otherwise stated